DK1563307T3 - Tumormarkörproteiner og deres anvendelse - Google Patents

Tumormarkörproteiner og deres anvendelse

Info

Publication number
DK1563307T3
DK1563307T3 DK03773863T DK03773863T DK1563307T3 DK 1563307 T3 DK1563307 T3 DK 1563307T3 DK 03773863 T DK03773863 T DK 03773863T DK 03773863 T DK03773863 T DK 03773863T DK 1563307 T3 DK1563307 T3 DK 1563307T3
Authority
DK
Denmark
Prior art keywords
cancer
marker proteins
tumour
fluids
preparation
Prior art date
Application number
DK03773863T
Other languages
English (en)
Inventor
John Forsyth Russell Robertson
Catherine Rosamund Louise Graves
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Application granted granted Critical
Publication of DK1563307T3 publication Critical patent/DK1563307T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK03773863T 2002-11-14 2003-11-13 Tumormarkörproteiner og deres anvendelse DK1563307T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226622A GB2395270B (en) 2002-11-14 2002-11-14 Tumour marker proteins and uses thereof
PCT/GB2003/004950 WO2004044590A1 (en) 2002-11-14 2003-11-13 Tumour marker proteins and uses thereof

Publications (1)

Publication Number Publication Date
DK1563307T3 true DK1563307T3 (da) 2008-09-29

Family

ID=9947849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03773863T DK1563307T3 (da) 2002-11-14 2003-11-13 Tumormarkörproteiner og deres anvendelse

Country Status (14)

Country Link
US (2) US8592169B2 (da)
EP (2) EP1967856A3 (da)
JP (1) JP4759267B2 (da)
AT (1) ATE397217T1 (da)
AU (1) AU2003282245B2 (da)
CA (1) CA2545930C (da)
CY (1) CY1108294T1 (da)
DE (1) DE60321375D1 (da)
DK (1) DK1563307T3 (da)
ES (1) ES2305530T3 (da)
GB (3) GB2424070B (da)
PT (1) PT1563307E (da)
SI (1) SI1563307T1 (da)
WO (1) WO2004044590A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
JP2006242869A (ja) * 2005-03-04 2006-09-14 Kyushu Univ 腫瘍マーカーとしての抗ｎａｓｐ抗体及び抗ｔｍｆ抗体
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2006132587A1 (en) * 2005-06-10 2006-12-14 Forskarpatent I Syd Ab Tumour marker in brca2 associated breast cancer
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
GB2441824A (en) * 2006-09-13 2008-03-19 Oncimmune Ltd Immunoassay method
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
CA2663154C (en) * 2006-09-13 2016-02-23 Oncimmune Ltd Improved immunoassay methods
JP2010519529A (ja) * 2007-02-23 2010-06-03 プレディクティブ バイオサイエンシーズ コーポレイション 臨床的介入を指向する診断方法
JP2010523990A (ja) * 2007-04-12 2010-07-15 プロテオシス アクチエンゲゼルシャフト アネキシンａ３による前立腺癌の自己免疫制御
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
AU2010204741B2 (en) * 2009-01-14 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2011116209A2 (en) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
US20130040839A1 (en) * 2011-06-27 2013-02-14 Ambergen, Inc. Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery
TW201312117A (zh) * 2011-07-28 2013-03-16 Univ Pennsylvania 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑
AU2015311679A1 (en) * 2014-09-04 2017-03-23 Provista Diagnostics, Inc. Biomarkers for detection of breast cancer
EP3271398B1 (en) 2015-03-17 2022-08-31 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3502701A3 (en) * 2015-12-11 2019-07-10 Sanford Health Reagents and methods for monitoring breast cancer therapy
WO2022013321A2 (en) 2020-07-14 2022-01-20 Oncimmune Limited Antibody assay
GB2600701A (en) 2020-11-04 2022-05-11 Oncimmune Ltd Antibody assay
CN113721021B (zh) * 2021-09-16 2023-07-07 郑州大学 Prkcz自身抗体在食管鳞癌辅助诊断中的应用
GB2622246A (en) 2022-09-08 2024-03-13 Oncimmune Germany Gmbh Antibody assay

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211453A (en) 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
ATE77700T1 (de) 1986-03-10 1992-07-15 Imre Corp Immunkomplextestverfahren.
WO1989001153A1 (en) 1987-07-24 1989-02-09 Xoma Corporation Methods for breast cancer detection
US4937185A (en) 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US5241052A (en) * 1988-03-04 1993-08-31 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
EP0678744B1 (en) * 1989-11-03 1999-09-15 MORTON, Donald L. Method for detecting urinary tumor associated antigens
US5157020A (en) 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (da) 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
DE4120412C1 (da) 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5753522A (en) * 1991-12-06 1998-05-19 Legacy Good Samaritan Hospital And Medical Center Purified protein for identifying a cancer-associated retinopathy autoantibody
CA2118015A1 (en) 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5763164A (en) 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5747268A (en) * 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
JPH07294530A (ja) 1994-04-20 1995-11-10 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk 病原体に対する体液中の抗体検出法
CA2148971A1 (en) 1994-05-26 1995-11-27 Izak Bahar Calibrator matrix
WO1996000084A1 (en) 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09189702A (ja) 1996-01-09 1997-07-22 Hitachi Chem Co Ltd 抗ムチン抗体の測定法、癌の測定法及び癌診断薬
JP2001517206A (ja) 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
EP1019727A1 (en) 1997-06-03 2000-07-19 Amdl, Inc Immunoassay for the detection of cancer
DK0991945T4 (da) * 1997-06-26 2008-06-09 Univ Michigan Fremgangsmåde til identifikation af tumor-antigener med autoantistoffer i serum
DE19805815C1 (de) 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
JP4083855B2 (ja) * 1998-02-16 2008-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 肺癌予後検査方法
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AUPP349098A0 (en) 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
GB9821170D0 (en) * 1998-09-30 1998-11-25 Univ Ulster Marker
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
AU773265B2 (en) * 1998-11-05 2004-05-20 Regents Of The University Of Michigan, The S100 proteins and autoantibodies as serum markers for cancer
US6387639B1 (en) 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
JP2000281255A (ja) * 1999-03-31 2000-10-10 Seiko Epson Corp 記録装置
US7807810B2 (en) 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) * 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
CA2431201A1 (en) 2000-12-13 2002-08-01 Bio-Rad Laboratories, Inc. Standard diluent for multiplex assays
US7745141B2 (en) 2001-06-21 2010-06-29 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
JP2005352771A (ja) 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd 発現プロファイルによるパターン認識システム
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
CA2663154C (en) 2006-09-13 2016-02-23 Oncimmune Ltd Improved immunoassay methods
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
CA2545930C (en) 2016-07-12
AU2003282245B2 (en) 2010-05-20
GB2395270B (en) 2006-08-16
CA2545930A1 (en) 2004-05-27
DE60321375D1 (de) 2008-07-10
GB0604694D0 (en) 2006-04-19
US8592169B2 (en) 2013-11-26
GB2424070B (en) 2007-06-27
EP1967856A2 (en) 2008-09-10
ATE397217T1 (de) 2008-06-15
EP1967856A3 (en) 2009-04-15
GB2424273B (en) 2007-06-27
US20140080736A1 (en) 2014-03-20
US20060094069A1 (en) 2006-05-04
AU2003282245A1 (en) 2004-06-03
ES2305530T3 (es) 2008-11-01
GB0226622D0 (en) 2002-12-24
CY1108294T1 (el) 2014-02-12
EP1563307B1 (en) 2008-05-28
JP4759267B2 (ja) 2011-08-31
EP1563307A1 (en) 2005-08-17
GB2395270A (en) 2004-05-19
PT1563307E (pt) 2008-07-16
JP2006506612A (ja) 2006-02-23
GB2424070A (en) 2006-09-13
SI1563307T1 (sl) 2008-10-31
GB0604693D0 (en) 2006-04-19
GB2424273A (en) 2006-09-20
WO2004044590A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
DK1563307T3 (da) Tumormarkörproteiner og deres anvendelse
ATE529161T1 (de) Tumorbehandlungs-identifikationssystem
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
CY1105129T1 (el) Οπτικος αισθητηρας για την επι τοπου μετρηση αναλυομενων ουσιων
DK1078264T3 (da) Tumormarkörer
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
ATE400813T1 (de) Tumormarker für frühes krebsstadium
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FI20050501L (fi) Etätunnistinjärjestelmä ja -menetelmä sekä etätunnistimen käyttö
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DK1853735T3 (da) Fremgangsmåder til detektering af progressionen af cervikal dysplasi i let grad
ATE382099T1 (de) Nachweis von invasivem krebs induziert von hpv und dessen vorläufer läsionen mit invasionspotential
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
Chen et al. Gastrointestinal cancer metastasis
WO2005078126A3 (en) Means for detecting and treating cancer cells resistant to therapeutic agents
ATE303451T1 (de) Nanopartikeln für optische sensoren
DE112007003223A5 (de) Prognostische Marker für die Klassifizierung des dreijährigen progressionsfreien Überlebens von Patienten mit kolorektalem Karzinom basierend auf Expressionsprofilen von biologischen Proben
RU2018105621A (ru) Способ диагностики рака предстательной железы
DE112007003238A5 (de) Prognostische Marker für die Vorhersage des fünfjährigen progressionsfreien Überlebens von Patienten mit kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben